PUBLISHER: Allied Market Research | PRODUCT CODE: 1139948
PUBLISHER: Allied Market Research | PRODUCT CODE: 1139948
The global lysosomal disease treatment market was valued at $7,572.97 million in 2021, and is projected to reach $14,090.39 million by 2031, registering a CAGR of 6.4% from 2022 to 2031.
Lysosomal disease is caused due to deficiency or absence of lysosomal acid lipase enzyme. The deficiency causes structural abnormalities of lysosome, result in storage of several toxic substances in the body cells. There are about 50 different types of these illnesses, which can harm heart, brain, skin, skeleton, and central nervous system among other physical organs. More lysosomal diseases are continuously being identified. Many lysosomal diseases currently lack an approved drug, despite the fact that clinical trials for prospective therapies for some of these disorders are now in progress.
A set of inherited metabolic diseases known as lysosomal storage disorders are brought on by enzyme deficits in different body cells. Key driver for growth of the global lysosomal disease treatment market includes increasing diagnosis rate, owing to increase in awareness and financial incentives for orphan drug development, which treats lysosomal diseases. In addition, rise in prevalence of lysosomal diseases, affordable product cost, increase in pharmaceutical companies for development of novel medications to treat lysosomal diseases are also responsible for growth of the market. Lack of treatment for lysosomal diseases and high cost of treatments are the factors that restrain growth of the market.
The lysosomal disease treatment market is segmented on the basis of disease type, type of therapy, end user, and region. By disease type, the market is divided into Gaucher's diseases, Fabry diseases, Pompe's syndrome, Mucopolysaccharidosis, and others. The others segment is further classified into aspartylglucosaminuria, batten disease, cystinosis, and glycogen storage disease II. By type of therapy, the market is fragmented into Enzyme replacement therapy, Stem cell therapy, Substrate reduction therapy, and others. By end user, it is segmented into Hospitals, Clinics, and others. Region wise, the market is analyzed across North America, Europe, Asia-Pacific, and LAMEA.
Major key players that operate in the global lysosomal disease treatment market include Amicus Therapeutics, Inc, Alexion Pharmaceuticals, Inc, BioMari, Chiese Farmaceutici SpA, Eli Lilly Company, Horizon Therapeutics Plc, Johnson & Johnson (Actelion Pharmaceuticals Ltd), Leadient Biosciences, Inc Novartis AG, Orphazyme A/S, Pfizer Inc, Recordati SpA, Sanofi (Genzyme Corporation), Sigilon Therapeutics, Inc, and Takeda Pharmaceutical Company Limited (Shire Plc) Valerion Therapeutics, Llc, and Viatris Inc (Mylan NV).
Key Benefits For Stakeholders
Key Market Segments
By Disease Type
By Type of Therapy
By End User
By Region